Sangamo Therapeutics, Inc. (SGMO)
NASDAQ$1.005+0.08 (8.66%)
Market Cap
$192.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
835 of 924
Rank in Industry
476 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SGMO Insider Trading Activity
SGMO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops …
Insider Activity of Sangamo Therapeutics, Inc.
Over the last 12 months, insiders at Sangamo Therapeutics, Inc. have bought $0 and sold $0 worth of Sangamo Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sangamo Therapeutics, Inc. have bought $41,780 and sold $2.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,784 shares for transaction amount of $25,029 was made by Markels John () on 2022‑06‑03.
List of Insider Buy and Sell Transactions, Sangamo Therapeutics, Inc.
| 2023-09-26 | Sale | BIOGEN INC. | 10 percent owner | 6M 2.4552% | $0.50 | $3M | -18.25% | |
| 2022-08-29 | Sale | Biogen MA Inc. | 500,000 0.3203% | $5.31 | $2.66M | -47.05% | ||
| 2022-06-03 | Markels John | 6,784 0.0045% | $3.69 | $25,029 | -5.24% | |||
| 2022-06-01 | PARKER H STEWART | 5,000 0.0034% | $3.60 | $17,996 | -0.28% | |||
| 2021-12-28 | Sale | BIOGEN INC. | 10 percent owner | 2,764 0.002% | $8.51 | $23,522 | -41.00% | |
| 2021-12-27 | Sale | BIOGEN INC. | 10 percent owner | 600 0.0004% | $8.56 | $5,136 | -41.81% | |
| 2021-12-23 | Sale | BIOGEN INC. | 10 percent owner | 81,187 0.0555% | $8.55 | $694,530 | -44.06% | |
| 2021-12-09 | Sale | BIOGEN INC. | 10 percent owner | 23,660 0.0171% | $8.56 | $202,541 | -38.39% | |
| 2021-12-08 | Sale | BIOGEN INC. | 10 percent owner | 75,814 0.0515% | $8.64 | $654,828 | -42.32% | |
| 2021-12-07 | Sale | BIOGEN INC. | 10 percent owner | 52,178 0.036% | $8.52 | $444,437 | -40.32% | |
| 2021-11-26 | Sale | BIOGEN INC. | 10 percent owner | 28,884 0.0202% | $8.60 | $248,434 | -37.99% | |
| 2021-03-23 | Sale | LOEB GARY | EVP, General Counsel & Sec. | 17,524 0.0128% | $13.13 | $230,042 | -23.91% | |
| 2020-12-31 | Sale | Ramelmeier Rolf Andrew | EVP, Technical Operations | 2,464 0.0018% | $16.74 | $41,247 | -32.49% | |
| 2020-12-24 | Sale | Ramelmeier Rolf Andrew | EVP, Technical Operations | 3,331 0.0025% | $18.13 | $60,391 | -40.20% | |
| 2020-12-17 | Sale | Ramasastry Saira | director | 10,000 0.0074% | $13.27 | $132,747 | -19.51% | |
| 2020-03-19 | Sale | DILLY STEPHEN GEORGE | director | 35,000 0.0295% | $6.00 | $210,000 | +79.12% | |
| 2020-03-18 | PARKER H STEWART | director | 3,000 0.0024% | $5.20 | $15,585 | +97.48% | ||
| 2020-03-17 | Zakrzewski Joseph S | director | 5,000 0.0039% | $4.99 | $24,950 | +99.55% | ||
| 2020-03-16 | Sale | DILLY STEPHEN GEORGE | director | 15,000 0.0154% | $6.02 | $90,261 | +116.83% | |
| 2020-03-13 | Zakrzewski Joseph S | director | 5,000 0.0037% | $5.67 | $28,350 | +63.57% |
Total: 372
Insider Historical Profitability
0.89%
| RA CAPITAL MANAGEMENT, LLC | 1829426 0.8768% | $1.69M | 31 | 48 | <0.0001% | |
| LANPHIER EDWARD O II | President & CEO | 235000 0.1126% | $217,093.00 | 1 | 42 | +107.09% |
| Wolff Henry Ward | Exec VP & CFO | 197872 0.0948% | $182,794.15 | 1 | 29 | +107.09% |
| PARKER H STEWART | 48700 0.0233% | $44,989.06 | 4 | 0 | +23.16% | |
| Markels John | 32484 0.0156% | $30,008.72 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$7,150,333 | 87 | -8.28% | $195.32M | |
$613,304,943 | 46 | 11.85% | $181.55M | |
Sangamo Therapeutics, Inc. (SGMO) | $48,218,096 | 42 | 0.89% | $192.75M |
$2,545,071 | 34 | 16.59% | $209.58M | |
$79,019,806 | 27 | 7.24% | $166.54M |
SGMO Institutional Investors: Active Positions
| Increased Positions | 73 | +58.4% | 23M | +40.56% |
| Decreased Positions | 50 | -40% | 18M | -31.28% |
| New Positions | 41 | New | 11M | New |
| Sold Out Positions | 19 | Sold Out | 971,856 | Sold Out |
| Total Postitions | 148 | +18.4% | 62M | +9.28% |
SGMO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $9,562.00 | 4.49% | 9.37M | -223,049 | -2.32% | 2024-12-31 |
| Wasatch Advisors Lp | $9,416.00 | 4.42% | 9.23M | -10M | -52.52% | 2024-12-31 |
| Blackrock, Inc. | $5,297.00 | 2.49% | 5.19M | +2M | +43.1% | 2024-12-31 |
| State Street Corp | $5,119.00 | 2.4% | 5.02M | +4M | +655.17% | 2024-12-31 |
| Renaissance Technologies Llc | $3,147.00 | 1.48% | 3.08M | -2M | -36.43% | 2024-12-31 |
| Millennium Management Llc | $2,794.00 | 1.31% | 2.74M | +828,337 | +43.34% | 2024-12-31 |
| Point72 Asset Management, L.P. | $2,316.00 | 1.09% | 2.27M | +2M | New | 2024-12-31 |
| Geode Capital Management, Llc | $2,256.00 | 1.06% | 2.21M | +73,540 | +3.44% | 2024-12-31 |
| Morgan Stanley | $1,919.00 | 0.9% | 1.88M | +2M | +433.32% | 2024-12-31 |
| Ikarian Capital, Llc | $1,897.00 | 0.89% | 1.86M | +2M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.